GPR35 Agonists for Neurodegeneration

GPR35 Agonists for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GPR35 Agonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">Kynurenic acid</td>
<td>Natural product</td>
</tr>
<tr>
<td class="label">Synthetic KYNA analogs</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Target</td>
<td>GPR35 (Kynurenic Acid Receptor)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>GPCR agonist</td>
</tr>
<tr>
<td class="label">Endogenous Ligand</td>
<td>Kynurenic acid (KYNA)</td>
</tr>
<tr>
<td class="label">Signaling</td>
<td>Gi-coupled, Gq-coupled</td>
</tr>
</table>

GPR35 is a G-protein coupled receptor that serves as the receptor for kynurenic acid (KYNA), a neuroactive metabolite of the tryptophan degradation pathway. GPR35 is widely expressed in the brain, particularly in microglia and neurons, where it mediates the neuroprotective effects of kynurenic acid. This receptor has emerged as a promising target for neurodegenerative disease therapy due to its roles in neuroinflammation, excitotoxicity, and oxidative stress. [@kl2018]

GPR35 Biology

GPR35 is encoded by the [GPR35](/genes/gpr35) gene. Key features include:

GPR35 Agonists for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GPR35 Agonists for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">Kynurenic acid</td>
<td>Natural product</td>
</tr>
<tr>
<td class="label">Synthetic KYNA analogs</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Allosteric modulators</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Target</td>
<td>GPR35 (Kynurenic Acid Receptor)</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>GPCR agonist</td>
</tr>
<tr>
<td class="label">Endogenous Ligand</td>
<td>Kynurenic acid (KYNA)</td>
</tr>
<tr>
<td class="label">Signaling</td>
<td>Gi-coupled, Gq-coupled</td>
</tr>
</table>

GPR35 is a G-protein coupled receptor that serves as the receptor for kynurenic acid (KYNA), a neuroactive metabolite of the tryptophan degradation pathway. GPR35 is widely expressed in the brain, particularly in microglia and neurons, where it mediates the neuroprotective effects of kynurenic acid. This receptor has emerged as a promising target for neurodegenerative disease therapy due to its roles in neuroinflammation, excitotoxicity, and oxidative stress. [@kl2018]

GPR35 Biology

GPR35 is encoded by the [GPR35](/genes/gpr35) gene. Key features include:

• Primary Endogenous Ligand: Kynurenic acid (KYNA)
• Gi-coupled: Inhibits adenylate cyclase, reduces cAMP
• Gq-coupled: Activates PLCβ in some contexts
• High Expression: Microglia, astrocytes, neurons
• Brain Distribution: Cortex, hippocampus, basal ganglia, cerebellum

Mechanism of Action

GPR35 agonists work through anti-inflammatory and neuroprotective signaling:

Key Mechanisms

Therapeutic Potential

Alzheimer's Disease

GPR35 agonists may benefit AD through:

• Reduction of amyloid-induced neuroinflammation
• Protection against excitotoxicity
• Support of cognitive function
• Modulation of kynurenine pathway

Parkinson's Disease

GPR35 is particularly relevant for PD:

• High expression in substantia nigra
• Protection of dopaminergic neurons
• Reduction of microglial activation in basal ganglia
• Potential to slow disease progression

Other Applications

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons-disease)
• Stroke
• Epilepsy

Drug Development

GPR35 agonists are in various stages of development:

Drug Properties

Research Challenges

• Kynurenic acid has limited BBB penetration
• Synthetic analogs need optimization
• Receptor desensitization with chronic use
• Species differences in pharmacology

References

Related Pages

• [Neuroinflammation Modulation](/therapeutics/neuroinflammation-modulation-therapies)
• [Kynurenine Pathway](/mechanisms/kynurenine-pathway)
• [Microglial Modulation](/therapeutics/microglial-modulation-therapy-neurodegeneration)
• [GPR35 Gene](/genes/gpr35)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
• [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;